Diabetic Patient (Type 1,2, MODY, Secondary) or With Corticosteroid-induced Diabetes Following Initiation of Corticosteroid Treatment Clinical Trial
— COVIDEXOfficial title:
Tele-expertise for Glycemic Control Monitoring in Patients With Diabetes Hospitalized for Covid-19 Infection
Verified date | April 2022 |
Source | University Hospital, Strasbourg, France |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Diabetes is a major factor of morbi-mortality in Covid-19 infection. Currently, steroid therapy is required in patients under oxygen therapy. This treatment is associated with hyper glycaemia in patients with diabetes. Recommendations for the management of diabetes during Covid-19 infection is to use insulin treatment. The majority of units involves in the management of patient with Covid19 infection are not the experience in managing intensive insulin therapy and the time to ensure this follow-up. All the data in the literature are in favor of a positive impact of telemedicine on the metabolic control of diabetic patients. However, the routine use of telemedicine and more particularly tele-expertise within hospital units is very underdeveloped in France. The epidemic of Covid-19 represents a unique situation where the health authorities recommend to physicians to use telemedicine to ensure the follow-up and optimal management of patients. The aim of this study was to compare the metabolic control of diabetic patients infected with Covid-19 followed in tele-expertise to a group of diabetic patients infected with Covid-19 managed in standard conditions.
Status | Terminated |
Enrollment | 48 |
Est. completion date | February 18, 2022 |
Est. primary completion date | February 18, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient adult hospitalized for Covid-19 infection in the Infectious Diseases Department of the University Hospital of Strasbourg (HUS) - Patient requiring steroid treatment - Diabetic patient (type 1,2, MODY, secondary) or with corticosteroid-induced diabetes following initiation of corticosteroid treatment Exclusion Criteria: - Contraindication to the use of the Free-Style Medical Device |
Country | Name | City | State |
---|---|---|---|
France | Hopitaux Universitaires de Strasbourg | Strasbourg |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Strasbourg, France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of time spent in the range 70-180 mg / dl (TIR) | measured every day in the group followed by tele-expertise compared with group under standard care (comparison of the daily evolution of the TIR in both groups). | At the end of hospitalization (maximum day 14) | |
Secondary | Mortality | At the end of hospitalization (maximum day 14) | ||
Secondary | Intensive Care Unit Transfers | At the end of hospitalization (maximum day 14) | ||
Secondary | Cardiovascular and infectious complications | At the end of hospitalization (maximum day 14) | ||
Secondary | Acute metabolic complications: keto acidosis, severe hypoglycaemia | At the end of hospitalization (maximum day 14) | ||
Secondary | Duration of hospitalization and treatments administered | At the end of hospitalization (maximum day 14) | ||
Secondary | Mean glucose | At the end of hospitalization (maximum day 14) | ||
Secondary | Time spent above glycaemia > 180mg/dl | At the end of hospitalization (maximum day 14) | ||
Secondary | Time spent bellow glycaemia < 70mg/dl | At the end of hospitalization (maximum day 14) |